13 February 2018 - - Sacramento, California-based biotechnology company Anpac Bio's proprietary cancer differentiation analysis (CDA) liquid biopsy technology now identifies over 26 different cancers with a single, standard blood test, the company said.
Comprehensive research validity data from 60,000+ cases independently-corroborated by hospitals and cancer researchers demonstrate Anpac Bio's CDA diagnostics consistently detect 26+ cancers with a sensitivity and specificity rate range of 75%-90%, without harmful side effects in patients, with far fewer "false positives", at a cost substantially lower than traditional testing, and generate results within minutes of sample submission.
By analyzing simple, standard, blood tests, and applying Anpac Bio's proprietary, multi-level, multi-parameter, diagnostic algorithms, Anpac Bio's CDA technology identifies cancer with measurably-greater accuracy than most current, conventional screening methods.
CDA's very early stage cancer and pre-cancerous disease detection efficiency and accuracy is due to the technology's multi-level, multi-parameter patented design. The integrated system measures numerous protein, molecular, cellular, and other factors, to identify disease signals.
Collected data is subsequently analyzed using Anpac Bio's proprietary algorithms. The resulting data is then assigned an overall CDA value, indicating cancer incidence risk level
Anpac Bio's unique, cross-disciplinary approach combines medicine, biochemistry, chemistry, materials, fluid mechanics, signal detection and processing, physics, precision machine engineering, and software engineering--to achieve vastly superior early cancer screening and detection technology.